Avoid haloperidol lactate injection if the patient has a known hypersensitivity to haloperidol or any components of the formulation. This includes a history of severe allergic reactions.
Exercise caution when administering haloperidol to patients with known or suspected CNS depression, including those with significant cardiovascular disease.
Closely monitor patients with Parkinson’s disease or other extrapyramidal disorders as haloperidol may worsen these conditions. Regular assessments are necessary.
Patients with a history of seizures should be carefully monitored, as haloperidol can lower the seizure threshold. Adjust dosage accordingly under strict medical supervision.
Prolonged QT interval prolongation is a risk. Obtain a baseline electrocardiogram (ECG) before initiating treatment, and consider ECG monitoring during therapy, especially in high-risk patients (e. g., those with pre-existing cardiac conditions, electrolyte imbalances).
Use with extreme caution in patients with hepatic or renal impairment. Dosage adjustments may be necessary, guided by clinical response and laboratory results.
| Elderly patients | Start with a low dose and carefully titrate upwards, due to increased sensitivity to antipsychotic effects. |
| Patients with diabetes | Monitor blood glucose levels closely, as haloperidol may affect glucose metabolism. |
| Patients dehydrated or hypovolemic | Increased risk of orthostatic hypotension. Monitor blood pressure frequently. |
Inform patients about potential side effects, including but not limited to extrapyramidal symptoms (EPS), tardive dyskinesia, neuroleptic malignant syndrome (NMS), and sedation. Stress the importance of reporting any unusual symptoms immediately.
Avoid concurrent use with medications that prolong the QT interval. Consult comprehensive drug interaction databases before combining with other medications.
